ZIOP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Jan 2022 @ 13:00):

Stats
今日成交量	2.13M
平均成交量	2.36M
市值	208.12M
EPS	$0 ( 2022-02-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.07
ATR14	$0.104 (12.01%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-22	De Groot Eleanor	Sell	20 132	Common Stock
2021-03-04	Thistle Mary	Buy	150 000	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	37 500	Stock Option (right to buy)
2021-03-04	Thistle Mary	Buy	5 000	Common Stock
2021-03-04	Buchi J Kevin	Buy	31 250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 95 transactions
Buy: 4 516 054 \| Sell: 1 683 458

音量相关性

長: 0.25 (neutral)

短: 0.41 (neutral)

Signal:(38.327) Neutral

ZIOPHARM Oncology Inc 相关性

10 最正相关
TLGT	0.939
JAGX	0.926
OLB	0.923
ALLR	0.922
MICS	0.922
FCBC	0.92
ONEM	0.917
AKTX	0.916
BWB	0.915
PSHG	0.914

10 最负相关
ITAQU	-0.963
CSLM	-0.949
OPRA	-0.945
SCRM	-0.942
VCTR	-0.942
RCEL	-0.941
XPAX	-0.941
COCO	-0.939
BRLI	-0.938
ALSA	-0.936

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ZIOPHARM Oncology Inc 相关性 - 货币/商品

-0.47
( neutral )

-0.83
( strong negative )

0.00
( neutral )

-0.30
( neutral )

-0.76
( moderate negative )

0.75
( moderate )

ZIOPHARM Oncology Inc 财务报表

Annual	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.380

FY	2019
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.700

FY	2018
营收:	$146 000
毛利润:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

ZIOPHARM Oncology Inc

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.